Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, annou...
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, announced the expansion of its mu...
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced a collaborative system-level framework for inject...
-Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined...
GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...
Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-led...
As artificial intelligence and advanced technologies transform the pharmaceutical industry, leaders face the challenge of harnessing innovation wit...
Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has achieved ...
BriaCell is advancing a new generation of cancer immunotherapies designed to improve outcomes for patients with metastatic breast cancer and other solid tu...
At ASCO, Dr. Nina Balanchivadze of Sarah Cannon Research Institute at Virginia Oncology Associates and Dr. Kyle Lavin of the UNC School of Medicine shared ...
Private equity firm Warburg Pincus is reportedly close to acquiring Pantherx Rare, a leading US specialty pharmacy focused on rare and orphan diseases, in ...
The US Food and Drug Administration (FDA) has expanded the approved indication for the Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) combination...
© 2026 Biopharma Boardroom. All Rights Reserved.
